Stromal Characteristics and Impact on New Therapies for Metastatic Triple-Negative Breast Cancer

SIMPLE SUMMARY: In this review, we summarize the recent outcomes from clinical trials with new agents for metastatic triple-negative breast cancer, specifically focusing on immunotherapies targeting the PD-1/PD-L1 pathway and antibody–drug conjugates. In addition to the clinical data supporting thes...

Descripción completa

Detalles Bibliográficos
Autores principales: Fertal, Shelby A., Poterala, Johanna E., Ponik, Suzanne M., Wisinski, Kari B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8909697/
https://www.ncbi.nlm.nih.gov/pubmed/35267548
http://dx.doi.org/10.3390/cancers14051238

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8909697/
https://www.ncbi.nlm.nih.gov/pubmed/35267548
http://dx.doi.org/10.3390/cancers14051238

Ejemplares similares